In my opinion IF this is Philips novel device and they can now (with the use of MIXNGO) start to build a portfolio of tests that can be put into cassettes to be used in the same machine, for multiple multiplex tests and produce tests to lab quality within 5 minutes then this is a breakthrough in the diagnostics industry
IF this occurs then it will mean that these tests no longer need to be sent to a lab, rather they can be completed at the point if care.
Troponin I is just the first that will help launch the device.
The problem that Philips has had is that they couldn't get it to work with their existing partners after years. But apparently with MIXNGO it has now become a reality and they are employing personal to ensure the approvals are met and that the marketing is right.
Philips sell over $30B of medical equipment outside of the IVD space currently ( for devices such as CAT and MRI scanners) so they have a large customer base already.
The POC troponin market is already nearing $1B worldwide.
It is a reality.
If anteo's MIXNGO can become the gold standard in surface chemistry for this POC space and other areas where you need to bind fragile proteins to harsh surfaces then the royalties will flow for years.
This is the big picture and blue sky.
ADO Price at posting:
16.0¢ Sentiment: Hold Disclosure: Held
